Adipotide
FTPP / Prohibitin-TP01
Adipotide (also known as FTPP or Prohibitin-TP01) is a chimeric peptide consisting of a prohibitin-targeting sequence fused to a pro-apoptotic peptide (D(KLAKLAK)2) that selectively destroys blood vessels supplying white adipose tissue, causing rapid and dramatic fat loss through vascular disruption. It was developed at the University of Texas MD Anderson Cancer Center and demonstrated remarkable fat reduction in obese rhesus monkeys, generating significant media attention. However, severe renal toxicity observed in primate studies has significantly tempered enthusiasm for its clinical development.
Mécanisme d'action
Peptidomimetic that targets prohibitin on adipose vasculature. Binds to ANXA2 receptors on blood vessels supplying white adipose tissue, triggering targeted apoptosis of fat tissue endothelial cells. Causes selective fat tissue vascular disruption and subsequent fat cell death.
Protocoles de recherche
Pour des fins de recherche uniquement. Pas de conseil médical.
Research protocols in primates used 0.43mg/kg subcutaneously daily for 28 days. Resulted in 11% body weight loss. Human dosing not established. Very aggressive mechanism with significant renal toxicity risk.
Notes de recherche
Clinical Research Status
Adipotide demonstrated dramatic efficacy in a landmark 2012 primate study published in Science Translational Medicine, showing 11% body weight loss and 38% reduction in abdominal fat in obese rhesus monkeys over 28 days of treatment. Despite these impressive results, the severe kidney damage observed in treated animals has prevented progression to human clinical trials. No active clinical trial registrations for Adipotide in humans have been identified, and its development status remains uncertain with no recent publications from the original research group.
Key Published Findings
The targeting peptide CKGGRAKDC binds to prohibitin on the surface of blood vessels specifically in white adipose tissue, while the attached D(KLAKLAK)2 sequence disrupts mitochondrial membranes in endothelial cells, causing vascular collapse and subsequent adipocyte death. Treated monkeys showed dramatic reductions in body weight, BMI, abdominal circumference, and improvements in insulin resistance. Imaging studies confirmed selective destruction of adipose vasculature with corresponding fat tissue necrosis and reabsorption over the treatment period.
Safety Profile
The most significant safety concern is dose-dependent renal proximal tubule degeneration, likely due to prohibitin expression in kidney vasculature or renal filtration and accumulation of the peptide. Treated primates developed elevated BUN and creatinine levels, with histological evidence of tubular necrosis that was partially reversible upon treatment cessation. Additional concerns include the irreversible nature of vascular destruction in adipose tissue and the unknown long-term consequences of acute fat tissue necrosis on systemic inflammation and metabolic homeostasis.
Comparison to Related Compounds
Adipotide's mechanism is fundamentally different from all other fat loss compounds: rather than modulating metabolism, appetite, or lipolysis, it physically destroys the blood supply to fat tissue. GLP-1 agonists like semaglutide achieve comparable weight loss through appetite suppression without organ toxicity, making them far safer alternatives despite slower onset. The targeted vascular disruption approach was originally developed for cancer therapy (tumor angiogenesis inhibition) and represents a repurposing that may carry inherent toxicity risks in non-tumor tissue.
Community Observations
Despite significant interest generated by the primate study results, human self-experimentation with Adipotide is extremely rare due to legitimate fears of irreversible kidney damage. Online communities generally regard Adipotide as a cautionary example of dramatic efficacy coupled with unacceptable toxicity, often referenced in discussions about risk-reward calculations in experimental compound use. The compound is occasionally available from gray market peptide sources, but knowledgeable community members consistently advise against its use given the availability of safer alternatives for fat loss.
Moitié de vie
~30-60 minutes
Réconstitution
Bacteriostatic water (BAC)
Conservation
Lyophilisé
Refrigerate 2-8C. Protect from light.
Réconstitué
Refrigerate 2-8C. Use within 7 days.
Statut légal aux États-Unis
Autres noms connus
Questions fréquentes
Qu'est-ce que Adipotide ?
Adipotide (also known as FTPP or Prohibitin-TP01) is a chimeric peptide consisting of a prohibitin-targeting sequence fused to a pro-apoptotic peptide (D(KLAKLAK)2) that selectively destroys blood vessels supplying white adipose tissue, causing rapid and dramatic fat loss through vascular disruption. It was developed at the University of Texas MD Anderson Cancer Center and demonstrated remarkable fat reduction in obese rhesus monkeys, generating significant media attention. However, severe renal toxicity observed in primate studies has significantly tempered enthusiasm for its clinical development.
Comment agit Adipotide ?
Peptidomimetic that targets prohibitin on adipose vasculature. Binds to ANXA2 receptors on blood vessels supplying white adipose tissue, triggering targeted apoptosis of fat tissue endothelial cells. Causes selective fat tissue vascular disruption and subsequent fat cell death.
Quel est le statut réglementaire de Adipotide aux États-Unis ?
Research chemical (not FDA-approved)
Quelle est la demi-vie de Adipotide ?
~30-60 minutes
Sous quels autres noms Adipotide est-il connu ?
FTPP, Prohibitin-TP01
Peptide Contacts fournit des résumés basés sur la recherche à des fins d’information uniquement. Nous ne hébergeons, n’épandons ni ne recommandons les documents des fournisseurs. Toutes les certificats d'analyse, certificats GMP et communications du fournisseur doivent être demandés et vérifiés directement par l'acheteur. Rien sur cette plateforme ne constitue un avis juridique, médical ou professionnel. Les utilisateurs sont entièrement responsables de la vérification des informations du fournisseur et de l’assurance de la conformité avec toutes les lois locales, d'état et fédérales applicables avant l'achat de tout produit chimique de recherche. L'utilisation de cette plateforme constitue l'acceptation pleine et entière de la responsabilité personnelle.
Lire la déclaration complète